US › Healthcare

Precision BioSciences Inc (DTIL)

US · Healthcare · Biotechnology

$6.67+0.60%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-32.7M

EPS

$-0.71

EPS estimate

$-0.74

EPS came in at -0.71 against a street estimate of -0.74 — a beat of 4.1%.

Key statistics

Market cap

$197.9M

Forward P/E

11.8

P/B

4.41

Book value

$1.71

EPS (TTM)

$-1.31

52-week high

$9.62

52-week low

$3.53

50-day MA

$7.84

200-day MA

$6.19

Beta

1.25

Analyst view

Analysts rate Precision BioSciences Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $29.40.

Shareholding

Insiders

8.03%

Institutions

68.68%

Largest institutional holders

Fund	Stake
Aberdeen Group PLC	8.08%
Bleichroeder LP	6.02%
Octagon Capital Advisors LP	4.89%
BOOTHBAY FUND MANAGEMENT, LLC	3.86%
Driehaus Capital Management LLC	3.61%
Lynx1 Capital Management, LP	3.44%
Vanguard Capital Management, LLC	3.30%
Empery Asset Management, LP	2.81%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Precision BioSciences Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.